Table 2 Characteristics of previously published studies for CI vs. IB of beta-lactam antibiotics
From: Continuous beta-lactam infusion in critically ill patients: the clinical evidence
Study | Setting (country) | Test antibiotic | Critically ill? | Patient population | Sample size | Age (yr) a | Allocation sequence generator | Allocation concealment | Masking | Concomitant antibiotics | |
|---|---|---|---|---|---|---|---|---|---|---|---|
CI | IT | ||||||||||
Angus et al. [87] | Not specified (Thailand) | Ceftazidime | Yes | Septicemic melioidosis | 21 | 48 (29–58) | 43 (27–73) | Not specified | Not specified | Not specified | Amx/clv or doxy, tmp/smx and chlora |
Bodey et al. [89] | Non-ICU (USA) | Cefamandole | No | Malignant diseases with neutropenia | 204 | Not specified | Adequate | Adequate | Not specified | Carbenicillin | |
Buck et al. [81] | Non-ICU (Germany) | Pip/tazo | No | Hospitalized infections | 24 | 60-88b | 32-76b | Not specified | Adequate | No | Nil stated |
Buijk et al. [52] | ICU (Netherlands) | Ceftazidime | Yes | Intra-abdominal infections | 18 | 12 (46–76) | 6 (42–87) | Not specified | Not specified | No | Various |
Georges et al. [80] | ICU (France) | Cefepime | Yes | Critically ill with gram-negative infections | 50 | 50 ± 17 | 46 ± 24 | Not specified | Not specified | No | Amikacin |
Hanes et al. [86] | ICU (USA) | Ceftazidime | Yes | Critically ill trauma | 32 | 33.5 ± 12.5 | 36.1 ± 12.8 | Not specified | Not specified | No | Nil stated |
Kojika et al. [82] | Not specified (Japan) | Meropenem | No | Intra-abdominal infections | 10 | 67.4 ± 14.6 | 60 ± 12.8 | Not specified | Not specified | No | Nil stated |
Lagast et al. [88] | Not specified (Belgium) | Cefoperazone | No | Gram-negative septicaemia | 45 | 37-77b | Not specified | Not specified | No | Nil stated | |
Lau et al. [79] | ICU (USA) | Pip/tazo | No | Complicated intra-abdominal infections | 262 | 50.4 ± 16.6 | 49.3 ± 17.8 | Not specified | Not specified | No | Nil stated |
Lubasch et al. [83] | Not specified (Germany) | Ceftazidime | No | Hospitalized patients with COPD exacerbation | 81 | 65.3 ± 10.1 | Not specified | Not specified | No | Nil stated | |
Nicolau et al. [84] | ICU (USA) | Ceftazidime | Yes | Critically ill patients with sepsis | 41 | 46 ± 16 | 56 ± 20 | Adequate | Not specified | No | Tobramycin |
Pedeboscq et al. [85] | ICU (France) | Pip/tazo | Yes | Severe sepsis | 7 | 58 ± 12 | Not specified | Not specified | No | Ofloxacin | |
Rafati et al. [78] | ICU (Iran) | Piperacillin | Yes | Critically ill patients with sepsis | 40 | 50.1 ± 22.2 | 48.0 ± 20.7 | Not specified | Not specified | No | Amikacin |
Roberts et al. [75] | ICU (Australia) | Ceftriaxone | Yes | Critically ill patients with sepsis | 57 | 43 ± 19 | 52 ± 16 | Adequate | Adequate | Adequatec | Multiple depending on indication |
Sakka et al. [77] | ICU (Germany) | Imi/cila | Yes | Critically ill patients with sepsis | 20 | 62 ± 16 | 59 ± 16 | Not specified | Adequate | No | Nil stated |
Van Zanten et al. [76] | Not specified (Netherlands) | Cefotaxime | No | Hospitalized patients with COPD exacerbation | 93 | 65.3 ± 8.4 | 68.6 ± 5.3 | Not specified | Not specified | No | Nil stated |